Differential expression of PDE5 in failing and nonfailing human myocardium - Wikidata - awgldk - TriplyDB

Differential expression of PDE5 in failing and nonfailing human myocardium

Differential expression of PDE5 in failing and nonfailing human myocardium

http://www.wikidata.org/entity/Q35680934

about

GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease The emperor's new clothes: PDE5 and the heart The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial Effects of sildenafil and/or muscle derived stem cells on myocardial infarction.Acute effects of sildenafil and dobutamine in the hypertrophic and failing right heart in vivo.Sex, drugs, and trial design: sex influences the heart and drug responses PDE5 inhibitor efficacy is estrogen dependent in female heart disease.Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs.The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension.Right ventricular cyclic nucleotide signaling is decreased in hyperoxia-induced pulmonary hypertension in neonatal mice.Drug Therapy for Heart Valve Diseases.Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling.Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G.Chemotherapeutic efficacy of phosphodiesterase inhibitors in chagasic cardiomyopathy.Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock.Phosphodiesterases and cyclic GMP regulation in heart muscle.Assessment and treatment of right ventricular failure.Management of pulmonary hypertension in left heart disease.Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension.Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy.PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design.Rho kinase mediates right ventricular systolic dysfunction in rats with chronic neonatal pulmonary hypertension.Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension.Transcriptional and Cell Cycle Alterations Mark Aging of Primary Human Adipose-Derived Stem Cells.cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway.

P2860

Q28254667-4DBDCA79-6B3E-44D7-97E3-6887A9D9C1F4 Q28543897-93CFF7E2-5F16-4954-AD08-B65291830228 Q28544798-42A02519-553A-473F-BDE8-B8D4FCDB831A Q30462352-C314B4DF-44A9-4E74-A933-F104AAC91A63 Q33806059-311248E8-ABF7-4096-9D29-3BAFF04D8538 Q33872473-1D79FDA7-D15C-4090-985D-7707AACC5D3A Q33872491-2FA9C2E3-D0D8-4B89-B789-C105334D331C Q34289307-4F848933-2AE7-4586-9F1B-AAF23349ECCF Q35156618-789A1A22-F23E-4515-8115-36F099FAE0E6 Q35705494-CC16B49A-B247-41D7-B299-3F06E2A1AA66 Q35749616-38AF94CD-030A-4414-9C34-D3D05A61FF43 Q36091454-4E0AF498-0CD5-4D35-8DBC-96401EAD9F58 Q36128551-E5CC5776-583A-4905-926E-B5DD3A394132 Q36191580-60D2492B-6182-46E8-A4D6-B2594D2CC41D Q36460566-6F5468BC-CB10-4969-A0F6-A878288B127F Q36609843-A60CB6A9-DFDF-48F4-84CF-B130AADA5B72 Q36808317-5F9667EC-C44B-4D78-9139-C8761E135745 Q36830763-49EC591B-639A-4CD3-B3CE-5F1F4C009B1E Q37058596-7CC55EAD-F826-436B-A380-E39F0B9DE663 Q37075920-DAC3621C-EC80-4E0D-81DA-C10E6CD5D9B5 Q37341337-26F01DA2-90C2-4A9F-A259-8B3090D36E93 Q37734554-15EF9D04-B17D-49A7-9697-38B8081009FE Q38033089-A1B4B2A2-4661-4D46-A26D-E68E5F4C8073 Q38080707-87627648-914C-461A-BB64-35BE3701D67F Q38099630-50AC06AE-1838-4DC8-9978-DD1AAE2F0BF9 Q38119018-51AC171C-DF8E-45F5-8504-906722DF5868 Q38542767-9D00E458-8937-49FF-A675-19FD52E085A6 Q38992600-9BF407FD-182C-45D3-90A4-234860ADA0A0 Q41819549-F4B7CD2B-14B9-4694-9D3F-F8DBE53C895E Q41927225-CCDC82B8-01D1-4BF6-95BA-3AA904297274 Q44589946-54315228-CB1C-4F89-BFDE-CAC668635C29 Q47617244-A0853119-056C-400C-A2EA-3ADA15FFBDF6 Q48224488-04A52785-DEC9-49F2-8156-BDF99FF1F1C1 Q54978990-F0CE01DB-B161-4E4E-9C17-7D68C4BD3F29

P2860

Differential expression of PDE5 in failing and nonfailing human myocardium

http://www.wikidata.org/entity/Q35680934

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Differential expression of PDE5 in failing and nonfailing human myocardium

@ast

Differential expression of PDE5 in failing and nonfailing human myocardium

@en

type

label

Differential expression of PDE5 in failing and nonfailing human myocardium

@ast

Differential expression of PDE5 in failing and nonfailing human myocardium

@en

prefLabel

Differential expression of PDE5 in failing and nonfailing human myocardium

@ast

Differential expression of PDE5 in failing and nonfailing human myocardium

@en

P1433

Q35680934-CF9ECF60-BDB5-46DB-BC7F-EFF53AB4CB7E

P1476

Q35680934-CE5B45EF-1699-4C4D-A4B9-B3F85B972887

P2093

Q35680934-0BD9AAE9-0303-450D-B70B-D41D088E979A

Q35680934-49DD321F-4C87-41F4-AC76-0D77CDD705C6

Q35680934-51E62C95-1E17-4742-97AA-A645E8BFEC1C

Q35680934-8E334683-2BB7-4AC6-99E3-B74EF2CC76E9

Q35680934-D52A201F-D7BB-4BA8-AD1B-FAC655521338

Q35680934-E0F92FD9-C34C-4B3E-AF69-55979B2BB33E

P2860

Q35680934-011568E4-3BB9-4D48-9D94-86C4FC313B5B

Q35680934-04FD751A-3241-4BBC-84A7-8B23C1FA5126

Q35680934-10F18F53-7CDA-47C1-A9EA-71865FFC6E21

Q35680934-27F90F2D-5DF3-4F8E-BC19-ACE6EBE0094D

Q35680934-2CD157B3-D9B5-4DEE-85ED-74B4C7B6D798

Q35680934-3509C78A-2E8B-4DFE-9FF2-4A5651794A1C

Q35680934-3892E3CF-3477-4887-BADB-A1B855564238

Q35680934-4AF34B2E-4E9B-410C-8BC6-E724BC5AC0D5

Q35680934-6FB46D20-9D6D-47A9-B993-305CFD3B9359

Q35680934-7675DF2A-DE6C-4CCD-8A11-0863C6606257

P304

Q35680934-F1B10441-8965-4BF5-9CB8-2D040E36EDAD

P31

Q35680934-2DBBB9A7-3D6F-4E2A-B65B-DF74523DF37D

P356

Q35680934-8FFF1F91-04A0-4A22-9188-42F6A217361E

P433

Q35680934-0AF8811E-BE04-4D3B-AD7D-C0AF6D71ADA4

P478

Q35680934-EC6615D7-45D3-42DF-AAA9-462C10961703

P577

Q35680934-C4B56697-4B36-45FB-8C25-466802DCE0E6

P698

Q35680934-2F8518B2-896A-4736-97DC-AA71D3CFF03D

P932

Q35680934-72BD7B41-16E2-4404-B628-62DAD8D306E4

P356

CIRCHEARTFAILURE.111.961706

P1433

Circulation: Heart Failure

P1476

Differential expression of PDE5 in failing and nonfailing human myocardium

@en

P2093

Benjamin French

http://www.w3.org/2001/XMLSchema#string

Jeffery K Monk

http://www.w3.org/2001/XMLSchema#string

Kenneth B Margulies

http://www.w3.org/2001/XMLSchema#string

Michael P Quaile

http://www.w3.org/2001/XMLSchema#string

Thomas P Cappola

http://www.w3.org/2001/XMLSchema#string

Xiaoyin Shan

http://www.w3.org/2001/XMLSchema#string

P2860

Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation

Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.

Apoptosis signal-regulating kinase 1 attenuates atrial natriuretic peptide secretion.

Cyclic GMP phosphodiesterase-5: target of sildenafil.

Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II

Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.

P304

79-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCHEARTFAILURE.111.961706

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22135403

http://www.w3.org/2001/XMLSchema#string

P932

3261338

http://www.w3.org/2001/XMLSchema#string